High-Dose EPA Supplements and Advanced Colon Cancer Survival Rates
Patients with advanced colon cancer who took four grams of eicosapentaenoic acid (EPA) daily achieved a 62% five-year overall survival rate, compared to 45% for those given a placebo, according to a study presented at a meeting of the European Society for Medical Oncology (ESMO) in Madrid and reported by HealthDay. The trial evaluated 418 U.K. patients who were scheduled for surgery to remove liver tumors that developed as a result of colon cancer.
Trial Design and Progression-Free Survival Findings
Participants in the trial were randomly assigned to consume either four grams of EPA or a mineral oil placebo every day before and after their liver surgery. While overall survival improved for the EPA group, median progression-free survival remained similar across both cohorts. Patients taking EPA experienced a median progression-free survival of 13.5 months, compared to 12.9 months for the placebo group. The duration that a patient lives with cancer without the disease worsening is known as progression-free survival.
Molecular Gastroenterology Expert Assessment
Mark Hull, lead author of the study and a professor of molecular gastroenterology at the University of Leeds in the U.K., explained in a news release that the survival advantage holds clinical significance for this specific patient population who have undergone surgery for bowel cancer that has metastasized to the liver, where recurrence rates are notoriously high. Hull noted that EPA is well-tolerated and safe, even when other cancer treatments are needed. He suggested the survival advantages may stem from how the body responds to cancer, especially if they suffer from weight loss, reduced appetite, and fatigue, noting parallels to cancer immunotherapy trials where overall survival improves without a significant change in progression-free survival.
University of Pisa Medical Oncology Evaluation
Dr. Chiara Cremolini, an associate professor of medical oncology at the University of Pisa in Italy who was not involved in the research, described the findings as intriguing from both biological and clinical perspectives in a statement issued by the European Society for Medical Oncology. Cremolini emphasized that confirmatory results are likely needed before incorporating this treatment option into daily clinical practice. Future investigations must account for the fact that individuals requiring liver tumor surgery often present with diverse medical backgrounds and distinct tumor biology, according to her remarks.
Frequently Asked Questions About the EPA Colon Cancer Study
What is eicosapentaenoic acid (EPA)?
EPA is a type of fatty acid evaluated in the trial at a high daily dosage of 4 grams.
Are the ESMO meeting findings considered final?
Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.
How many patients participated in the U.K. trial?
A total of 418 patients in the U.K. who were set to undergo procedures for the excision of colon cancer-derived liver growths were enrolled in the research.